Pharmacotherapy of chronic spontaneous urticaria

Bibliography

• Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009;64(10):1417-26
   PubMed Web of Science ®Google Scholar
• O'Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997;136(2):197-201
   PubMed Web of Science ®Google Scholar
• Baiardini I, Giardini A, Pasquali M, et al. Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. Allergy 2003;58(7):621-3
   PubMed Web of Science ®Google Scholar
• Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy 2009;39(6):777-87
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Schadendorf D, Haas N, et al. Enhanced P-selectin expression in chronic and dermographic urticaria. Int Arch Allergy Immunol 1997;114(1):86-9
   PubMed Web of Science ®Google Scholar
• Sheldon JM, Mathews KP, Lovell RG. The vexing urticaria problem: present concepts of etiology and management. J Allergy 1954;25(6):525-60
   PubMedGoogle Scholar
• Hide M, Francis DM, Grattan CE, et al. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993;328(22):1599-604
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009;64(10):1427-43
   PubMed Web of Science ®Google Scholar
• Grattan CE, Humphreys F; British Association of Dermatologists Therapy G, Audit S. Guidelines for evaluation and management of urticaria in adults and children. Br J Dermatol 2007;157(6):1116-23
   PubMed Web of Science ®Google Scholar
• Chow SK. Management of chronic urticaria in Asia: 2010 AADV consensus guidelines. Asia Pac Allergy 2012;2(2):149-60
   PubMedGoogle Scholar
• Guerra L, Vincenzi C, Marchesi E, et al. Loratadine and cetirizine in the treatment of chronic urticaria. J Eur Acad Dermatol 1994;3:148-52
   Google Scholar
• Dubertret L, Murrieta Aguttes M, Tonet J. Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study. J Eur Acad Dermatol Venereol 1999;12(1):16-24
   PubMed Web of Science ®Google Scholar
• Breneman DL. Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria. Ann Pharmacother 1996;30(10):1075-9
   PubMed Web of Science ®Google Scholar
• Ortonne JP, Grob JJ, Auquier P, Dreyfus I. Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. Am J Clin Dermatol 2007;8(1):37-42
   PubMed Web of Science ®Google Scholar
• Kaplan AP, Spector SL, Meeves S, et al. Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. Ann Allergy Asthma Immunol 2005;94(6):662-9
   PubMed Web of Science ®Google Scholar
• Nettis E, Colanardi MC, Barra L, et al. Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Br J Dermatol 2006;154(3):533-8
   PubMed Web of Science ®Google Scholar
• Brostoff J, Fitzharris P, Dunmore C, et al. Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urticaria. Allergy 1996;51(5):320-5
   PubMed Web of Science ®Google Scholar
• Gimenez-Arnau A, Pujol RM, Ianosi S, et al. Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study. Allergy 2007;62(5):539-46
   PubMed Web of Science ®Google Scholar
• Bousquet PJ, Bachert C, Canonica GW, et al. Uncontrolled allergic rhinitis during treatment and its impact on quality of life: a cluster randomized trial. J Allergy Clin Immunol 2010;126(3):666-8; e661-5
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Oanta A, Bogacka E, et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010;65(4):516-28
   PubMed Web of Science ®Google Scholar
• Horak F, Zieglmayer P, Zieglmayer R, Lemell P. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res 2010;59(5):391-8
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Greaves MW, Juhlin L, et al. Definition, classification, and routine diagnosis of urticaria: a consensus report. J Investig Dermatol Symp Proc 2001;6(2):123-7
   PubMedGoogle Scholar
• Church MK, Maurer M, Simons FE, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy 2010;65(4):459-66
   PubMed Web of Science ®Google Scholar
• Krause K, Spohr A, Zuberbier T, et al. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy 2013;68:921-8
   PubMed Web of Science ®Google Scholar
• Asero R. Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses. Clin Exp Dermatol 2007;32(1):34-8
   PubMed Web of Science ®Google Scholar
• Siebenhaar F, Degener F, Zuberbier T, et al. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J Allergy Clin Immunol 2009;123(3):672-9
   PubMed Web of Science ®Google Scholar
• Magerl M, Pisarevskaja D, Staubach P, et al. Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H-1-antihistamine dose escalation. Br J Dermatol 2012;166(5):1095-9
   PubMed Web of Science ®Google Scholar
• Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol 2010;125(3):676-82
   PubMed Web of Science ®Google Scholar
• Tanizaki H, Nakahigashi K, Miyachi Y, Kabashima K. Comparison of the efficacy of fexofenadine 120 and 240 mg/day on chronic idiopathic urticaria and histamine-induced skin responses in Japanese populations. J Dermatolog Treat 2013; [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Godse KV, Nadkarni NJ, Jani G, Ghate S. Fexofenadine in higher doses in chronic spontaneous urticaria. Indian Dermatol Online J 2010;1(1):45-6
   PubMedGoogle Scholar
• Gimenez-Arnau A, Izquierdo I, Maurer M. The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo- controlled treatment with rupatadine 10 and 20 mg. J Eur Acad Dermatol Venereol 2009;23(9):1088-91
   PubMed Web of Science ®Google Scholar
• Fedorowicz Z, van Zuuren EJ, Hu N. Histamine H2-receptor antagonists for urticaria. Cochrane Database Syst Rev 2012;3:CD008596
   PubMed Web of Science ®Google Scholar
• Engin B, Ozdemir M. Prospective randomized non-blinded clinical trial on the use of dapsone plus antihistamine vs. antihistamine in patients with chronic idiopathic urticaria. J Eur Acad Dermatol Venereol 2008;22(4):481-6
   PubMed Web of Science ®Google Scholar
• Cassano N, D'Argento V, Filotico R, Vena GA. Low-dose dapsone in chronic idiopathic urticaria: preliminary results of an open study. Acta Derm Venereol 2005;85(3):254-5
   PubMed Web of Science ®Google Scholar
• Kosnik M, Subic T. Add-on montelukast in antihistamine-resistant chronic idiopathic urticaria. Respir Med 2011;105(Suppl 1):S84-8
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, D'Alcamo A, Rizzo M, et al. Leukotriene receptor antagonists in monotherapy or in combination with antihistamines in the treatment of chronic urticaria: a systematic review. J Asthma Allergy 2008;2:9-16
   PubMedGoogle Scholar
• Grattan CE, O'Donnell BF, Francis DM, et al. Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria. Br J Dermatol 2000;143(2):365-72
   PubMed Web of Science ®Google Scholar
• Vena GA, Cassano N, Colombo D, et al. Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2006;55(4):705-9
   PubMed Web of Science ®Google Scholar
• Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011;128(1):202-9; e205
   PubMed Web of Science ®Google Scholar
• Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011;128(3):567-73; e561
   PubMed Web of Science ®Google Scholar
• Kaplan AP, Joseph K, Maykut RJ, et al. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008;122(3):569-73
   PubMed Web of Science ®Google Scholar
• Maurer M, Rosen K, Hsieh HJ. Omalizumab for chronic urticaria. N Engl J Med 2013;368(26):2530
   PubMedGoogle Scholar
• Staubach P, Eckhardt-Henn A, Dechene M, et al. Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol 2006;154(2):294-8
   PubMed Web of Science ®Google Scholar
• Takeda T, Sakurai Y, Takahagi S, et al. Increase of coagulation potential in chronic spontaneous urticaria. Allergy 2011;66(3):428-33
   PubMed Web of Science ®Google Scholar
• Takahagi S, Mihara S, Iwamoto K, et al. Coagulation/fibrinolysis and inflammation markers are associated with disease activity in patients with chronic urticaria. Allergy 2010;65(5):649-56
   PubMed Web of Science ®Google Scholar
• Parslew R, Pryce D, Ashworth J, Friedmann PS. Warfarin treatment of chronic idiopathic urticaria and angio-oedema. Clin Exp Allergy 2000;30(8):1161-5
   PubMed Web of Science ®Google Scholar
• Barlow RJ, Greaves MW. Warfarin in the treatment of chronic urticaria/angio-edema. Br J Dermatol 1992;126(4):415-16
   PubMed Web of Science ®Google Scholar
• Fagiolo U, Cancian M, Bertollo L, et al. Inhibitory effect of heparin on skin reactivity to autologous serum in chronic idiopathic urticaria. J Allergy Clin Immunol 1999;103(6):1143-7
   PubMed Web of Science ®Google Scholar
• Reeves GE, Boyle MJ, Bonfield J, et al. Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. Intern Med J 2004;34(4):182-6
   PubMed Web of Science ®Google Scholar
• Kozel MM, Sabroe RA. Chronic urticaria: aetiology, management and current and future treatment options. Drugs 2004;64(22):2515-36
   PubMed Web of Science ®Google Scholar
• Beck HI, Cramers M, Herlin T, et al. Comparison of oxatomide and clemastine in the treatment of chronic urticaria. A double blind study. Dermatologica 1985;171(1):49-51
   PubMedGoogle Scholar
• Demaubeuge J, Tennstedt D, Broux R. Does mast cell protection plus mediator antagonism surpass the effect of a classic antihistaminic in the treatment of chronic urticaria? A double-blind comparison of oxatomide and mequitazine. Dermatologica 1982;164(6):386-94
   PubMedGoogle Scholar
• Peremans W, Mertens RL, Morias J, Campaert H. Oxatomide in the treatment of chronic urticaria. A double-blind placebo-controlled trial. Dermatologica 1981;162(1):42-50
   PubMedGoogle Scholar
• Bressler RB, Sowell K, Huston DP. Therapy of chronic idiopathic urticaria with nifedipine: demonstration of beneficial effect in a double-blinded, placebo-controlled, crossover trial. J Allergy Clin Immunol 1989;83(4):756-63
   PubMed Web of Science ®Google Scholar
• Czarnetzki BM, Algermissen B, Jeep S, et al. Interferon treatment of patients with chronic urticaria and mastocytosis. J Am Acad Dermatol 1994;30(3):500-1
   PubMed Web of Science ®Google Scholar
• Torrelo A, Harto A, Ledo A. Interferon therapy for chronic urticaria. J Am Acad Dermatol 1995;32(4):684-5
   PubMed Web of Science ®Google Scholar
• Siebenhaar F, Magerl M, Peters EM, et al. Mast cell-driven skin inflammation is impaired in the absence of sensory nerves. J Allergy Clin Immunol 2008;121(4):955-61
   PubMed Web of Science ®Google Scholar
• Vieira Dos Santos R, Magerl M, Martus P, et al. Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. Br J Dermatol 2010;162(3):674-6
   PubMed Web of Science ®Google Scholar
• Metz M, Siebenhaar F, Maurer M. Mast cell functions in the innate skin immune system. Immunobiology 2008;213(3-4):251-60
   PubMed Web of Science ®Google Scholar
• Metz M, Maurer M. Innate immunity and allergy in the skin. Curr Opin Immunol 2009;21(6):687-93
   PubMed Web of Science ®Google Scholar
• Konstantinou GN, Asero R, Maurer M, et al. EAACI/GA(2)LEN task force consensus report: the autologous serum skin test in urticaria. Allergy 2009;64(9):1256-68
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Asero R, Bindslev-Jensen C, et al. The EAACI/GA²LEN/EDF/WAO Guideline for the definition, classification, diagnosis and management of Urticaria. The 2013 revision and update. Allergy 2013; In press
   Web of Science ®Google Scholar
• Henz BM, Metzenauer P, O'Keefe E, Zuberbier T. Differential effects of new-generation H1-receptor antagonists in pruritic dermatoses. Allergy 1998;53(2):180-3
   PubMed Web of Science ®Google Scholar
• Camarasa JM, Aliaga A, Fernandez-Vozmediano JM, et al. Azelastine tablets in the treatment of chronic idiopathic urticaria. Phase iii, randomised, double-blind, placebo and active controlled multicentric clinical trial. Skin Pharmacol Appl Skin Physiol 2001;14(2):77-86
   PubMedGoogle Scholar
• Juhlin L, Arendt C. Treatment of chronic urticaria with cetirizine dihydrochloride a non-sedating antihistamine. Br J Dermatol 1988;119(1):67-71
   PubMed Web of Science ®Google Scholar
• Alomar A, De La C, Fernandez J. Cetirizine vs astemizole in the treatment of chronic idiopathic urticaria. J Int Med Res 1990;18(5):358-65
   PubMed Web of Science ®Google Scholar
• Goh CL, Wong WK, Lim J. Cetirizine vs placebo in chronic idiopathic urticaria–a double blind randomised cross-over study. Ann Acad Med Singapore 1991;20(3):328-30
   PubMedGoogle Scholar
• Juhlin L. Cetirizine in the treatment of chronic urticaria. Clin Ther 1991;13(1):81-6
   PubMed Web of Science ®Google Scholar
• Andri L, Senna GE, Betteli C, et al. A comparison of the efficacy of cetirizine and terfenadine. A double-blind, controlled study of chronic idiopathic urticaria. Allergy 1993;48(5):358-65
   PubMed Web of Science ®Google Scholar
• Lambert D, Hantzperg M, Danglas P, Bloom M. Double-blind comparative study of terfenadine and cetirizine in chronic idiopathic urticaria. Allerg Immunol 1993;25(6):235-40
   PubMedGoogle Scholar
• La Rosa M, Leonardi S, Marchese G, et al. Double-blind multicenter study on the efficacy and tolerability of cetirizine compared with oxatomide in chronic idiopathic urticaria in preschool children. Ann Allergy Asthma Immunol 2001;87(1):48-53
   PubMed Web of Science ®Google Scholar
• Handa S, Dogra S, Kumar B. Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria. J Dermatolog Treat 2004;15(1):55-7
   PubMedGoogle Scholar
• Ring J, Hein R, Gauger A, et al. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001;40(1):72-6
   PubMed Web of Science ®Google Scholar
• Peyri J, Vida J, Marrón J, et al. Ebastine in chronic urticaria: a double-blind placebo controlled study. J Dermatol Treat 1991;2:51-3
   Google Scholar
• Kalis B. Double-blind multicentre comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticaria in adults. Drugs 1996;52(Suppl 1):30-4
   PubMedGoogle Scholar
• Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2000;84(5):517-22
   PubMed Web of Science ®Google Scholar
• Thompson AK, Finn AF, Schoenwetter WF. Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. J Am Acad Dermatol 2000;43(1 Pt 1):24-30
   PubMed Web of Science ®Google Scholar
• Kawashima M, Harada S. Efficacy and safety of fexofenadine HCl in Japanese patients with chronic idiopathic urticaria. Int Arch Allergy Immunol 2001;124:343-5
   Web of Science ®Google Scholar
• Degonda M, Pichler WJ, Bircher A, Helbling A. Chronic idiopathic urticaria: effectiveness of fexofenadine. A double-blind, placebo controlled study with 21 patients. Praxis 2002;91(15):637-43
   PubMedGoogle Scholar
• Ring J, Brockow K, Ollert M, Engst R. Antihistamines in urticaria. Clin Exp Allergy 1999;29(Suppl 1):31-7
   PubMedGoogle Scholar
• Leynadier F, Duarte-Risselin C, Murrieta M. Comparative therapeutic effect and safety of mizolastine and loratadine in chronic idiopathic urticaria. URTILOR study group. Eur J Dermatol 2000;10(3):205-11
   PubMed Web of Science ®Google Scholar
• Dubertret L, Zalupca L, Cristodoulo T, et al. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. Eur J Dermatol 2007;17(3):223-8
   PubMed Web of Science ®Google Scholar
• Kapp A, Pichler WJ. Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicenter study. Int J Dermatol 2006;45(4):469-74
   PubMed Web of Science ®Google Scholar